BioCryst Pharmaceuticals BCRX Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total revenues by Product | |||||
| Collaborative and other revenues | $7.71M-4.2% | $8.04M+19.8% | $6.72M+115% | $3.12M-85.0% | |
| ORLADEYO | $601.84M+37.5% | $437.66M+34.3% | $325.99M+29.5% | $251.63M+105% | |
| Other revenues | $29.02M+122% | $13.05M+141% | $5.42M-71.8% | $19.19M-44.6% | |
| Product sales, net | $623.15M+40.8% | $442.67M+36.3% | $324.7M+21.3% | $267.71M+96.3% | |
| Total trade receivables by Product | |||||
| ORLADEYO | $358.45M+32.7% | $270.02M+29.3% | $208.87M+34.7% | $155.07M+91.2% | |
| Peramivir | $12.23M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does BioCryst Pharmaceuticals break its business down?
- BioCryst Pharmaceuticals (BCRX) reports total revenues by product across 5 parts — Collaborative and other revenues, License and other revenues, ORLADEYO, Other revenues and Product sales, net. Each is extracted from the segment footnotes and tracked over time.
- Where does BioCryst Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in BioCryst Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
